deltatrials
Completed PHASE4 NCT00304655

Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)

Multicenter, Single Group Study of Aripiprazole Efficacy and Safety in the Acute Psychosis Treatment of Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder.

Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Conditions Schizoaffective Disorder Schizophrenia
Interventions Aripiprazole
Updated 6 times since 2017 Last updated: Dec 15, 2009 Started: Jul 31, 2004 Primary completion: May 31, 2006 Completion: Oct 31, 2007

Listed as NCT00304655, this PHASE4 trial focuses on Schizoaffective Disorder and Schizophrenia and remains completed. Sponsored by Korea Otsuka Pharmaceutical Co., Ltd., it has been updated 6 times since 2004, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE4

    First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Korea Otsuka Pharmaceutical Co., Ltd.
Data source: Korea Otsuka Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Seoul, South Korea